Abstract: Epstein-Barr virus (EBV), a human herpesvirus with potent B cell growth transforming ability, induces multiple cellular immune responses in the infected host. How these host responses work together to prevent virus pathogenicity, and how immune imbalance predisposes to disease, remain poorly understood. Here, we describe three ongoing lines of enquiry that are shedding new light on these issues. These focus on: (i) patients with infectious mononucleosis or its fatal equivalent, X-linked lymphoproliferative disease; (ii) EBV infection in a range of new, genetically defined, primary immune deficiency states; and (iii) experimental infection in two complementary animal models, the rhesus macaque and the human haemopoietic stem cell reconstituted mouse. 
Biology of EBV infection : an overview
Herpesviruses are ancient pathogens whose apparently benign relationship with their host species reflects the fine balance struck between host immune controls over virus infection and the virus' ability to evade those controls. Real insight into the immunological battle raging beneath the surface comes when that evolutionary compact is disturbed and disease ensues. Nowhere is this better illustrated than by Epstein-Barr virus (EBV), the human gamma-1 herpesvirus carried by most people as a life-long asymptomatic infection. Figure 1 presents the basic framework of EBV infection as currently understood. The main features, in chronologic order, are (i) initial replication of orally transmitted virus in permissive cells (probably squamous epithelial cells and some locally-infiltrating B lymphocytes) within the oropharynx,, (ii) colonisation of the host through growth-transforming latent infection of B cells in oropharyngeal lymphoid tissues, (iii) life-long persistence within the re-circulating memory B cell pool as a silent latent infection, and (iv) occasional reactivation from latency into virus replicative ("lytic") cycle, seeding secondary foci of virus replication at oropharyngeal sites.
In the process the virus presents an antigenically rich challenge to the immune system. Thus virus replication involves the sequential expression of two immediate early, >30 early and >30 late lytic cycle proteins, while classical B cell growth-transformation is achieved through the collective actions of 8 latent proteins, namely the nuclear antigens EBNAs 1, 2, 3A, 3B, 3C and -LP plus the latent membrane proteins, LMPs1 and 2. Many of these viral proteins elicit antibody and/or cell-mediated immune responses. Among the humoral responses, neutralising antibodies, predominantly directed against the virus' major envelope glycoprotein gp340 (a late lytic cycle product), are almost certainly important in longer-term protection of the host from reinfection by exogenous virus; however, such antibodies are quite slow to develop to high affinity during primary infection. Accordingly, cell-mediated responses appear to be more important in bringing the primary infection under control and also in containing reactivation of the virus from its latent reservoir during long-term virus carriage.
The main effectors of these cellular responses, NK cells, CD4 + and CD8 + T cells, are superimposed onto Figure 1 to show their potential sites of action against infected cells. How important these individual players are, and how they work together to contain EBV as an asymptomatic infection, is still poorly understood. Here we review recent lessons on this subject that have come either from patients in whom natural infection erupts into disease or from experimental infection in two increasingly promising animal models.
Infectious mononucleosis
Primary EBV infection in its natural setting, early in life, is almost always asymptomatic. However, if delayed until adolescence or later, as often happens in affluent societies, it sometimes presents as infectious mononucleosis (IM). This disease is characterized by large expansions of activated CD8 + T cells and to some extent NK cells appearing in the blood; indeed the classical symptoms (fever, pharyngitis, lymphadenopathy) may be caused more by cytokine release from those activated cells than from the virus infection per se. However the course of IM can vary from mild to severe, and little is known about the risk factors for disease development or severity. The most recent insights have come from a 4-year follow-up of 143 EBVseronegative college students, involving regular screening at 8 week intervals and immediate bleeds on signs of illness [1] . Of the 66/143 students who seroconverted to EBV-positivity over that time, 51 developed two or more IM symptoms. Disease severity correlated positively with virus load in circulating B cells, with the size of the CD8 + T cell response and also with NK cell numbers in the blood. Although these findings could not distinguish between virus infection and immune pathology as the determinant of symptoms, they did suggest that both CD8 + T cells and NK cells were responding similarly to the intensity of the viral challenge. The latter point remains controversial, however, since earlier work (albeit on a smaller patient cohort) reported an inverse correlation between virus load and NK cell numbers in IM blood, and inferred from this that severe IM resulted from a deficiency of early NK-mediated control [2] . Further studies are needed to resolve this important issue, focusing on the phenotype as well as the number of NK cells in IM blood, and (in the rare cases where this is possible) extending the work to include an analysis of NK cell, CD8 + T cell and EBV-infected B cell populations in IM tonsils, where the real action is likely to be found.
As comparators with IM, cases of asymptomatic primary infections are potentially very informative but they are difficult to identify without regular screening of large EBV-naïve cohorts. 
Components of the cell-mediated response to EBV

NK and invariant (i-)NKT cell responses
NK cell control of EBV during primary infection may operate at several levels, targeting either virus replicative foci in the oropharynx or the latent growth-transforming infections through which the virus first colonises the B cell system (see Figure 1 ). Of the two, virus replication would seem the more likely target if only because expression of surface HLA I molecules, the ligands for NK inhibitory receptors, falls in lytically-infected cells. In vitro models of lytic infection are limited but early studies showed that, at least in a virus-infected Burkitt's lymphoma cell line, the subset of cells entering lytic cycle are indeed sensitised to NK recognition [7] . This was coincident not just with surface HLA I down-regulation but also with up-regulation of ligands for the NK activating receptors NKG2D and DNAM-1 [7] . If NK cells have indeed exerted evolutionary pressure on EBV, one might expect viral counter-measures against such recognition, and perhaps the first hint of such NK evasion has recently emerged. Recent evidence suggests that iNKT cells with the V9/V2 T cell receptor, recognising the -GalCer-CD1d complex, may also mediate some control over the same in vitro transformation process. Thus, although iNKT cell numbers in peripheral blood mononuclear cell (PBMC) preparations are typically <0.3%, their depletion using an -GalCer-CD1d tetramer reportedly led to a 2-fold increase in the number of activated EBV-infected B cells in PBMC cultures 8 days post-infection [12] . The mechanism underlying this effect remains to be determined, but presumably must operate within 1-2 days of infection before EBV-activated B cells downregulate CD1d expression. Importantly, this down-regulation is not evidence of iNKT cell evasion by the virus but the programmed response of resting human B cells to any activating signal [13] .
CD8 + T cell responses
The cytotoxic CD8 + T cell response to primary EBV infection as seen in IM patients has been extensively reviewed [14, 15] and only certain aspects will be discussed here. Most activated CD8 + T cells in IM blood are EBV-specific, with lytic-antigen dominant over latent-antigen specificities. This dominance becomes less marked as the acute infection subsides and the highly expanded lytic-antigen response is more heavily culled. These changes, graphed in Figure 2 , are consistent with the presumed order of events in primary EBV infection. Early replicative foci would be expected to activate responses first from NK cells and then from lytic antigen-specific CD8 + T cells; thereafter, the virus colonises the B cell pool through latent growth-transforming infections that elicit the latent antigen-specific CD8 response. 
CD4 + T cell responses
By contrast, the CD4 + T cell response to EBV seems to be spread much more evenly across the whole range of available lytic cycle as well as latent antigens, as one might expect from a classically cross-primed response [25, 26] . There is no marked increase in total CD4 + T cell counts in acute IM but, with the development of HLA II tetramers, activated EBV epitopespecific CD4 + T cells have been detected at this time [27] . While these individual epitopespecific responses rarely exceed 1% of all CD4 + T cells, collectively they do impact on the activation status of the circulating CD4 + population in the acute phase. Thereafter tetramerstaining cell numbers fall rapidly within a few days, suggesting that the response peaks very early in the disease course. Again in contrast to the CD8 response, latent antigen-specific CD4 responses tend to be larger than those directed against lytic antigens both in IM and, after contraction, in T cell memory [27] . It is notable that, at least after in vitro expansion, many EBVspecific CD4 + T cell clones have cytotoxic as well as cytokine-secreting abilities [26, 27] . This implies that the CD4 + T cell response may play more than one role in vivo, with some cells providing help for the antibody responses to EBV antigens typically seen in IM, and others acting as direct cytolytic effectors against virus-infected B cells.
Intriguingly, the primary CD4 response to EBNA1 displays quite different kinetics, often not appearing until months after disease resolution [27] . This matches the well-known serologic picture in IM, where the IgG response to EBNA1 is unusually delayed and indeed may never appear in rare patients with chronic IM-like symptoms [28] [29] [30] . An absence of specific T cell help might therefore underlie this previously unexplained feature of the EBNA1 antibody response. As to why the EBNA1-induced T cell response is so delayed, a clue came from studies looking at the recognition of LCLs by CD4 + T cell clones specific for EBV antigens naturally expressed by these cells. Clones specific for lytic cycle antigens and many clones against latent proteins recognised LCLs well. In each case, however, this did not reflect direct recognition of antigen-expressing cells; rather, the relevant antigen was being released into supernatant medium, then taken up and processed as exogenously-acquired protein by co-resident cells in the culture. By contrast, EBNA1 was not detectably released and so its presentation to CD4 + T cells was entirely dependent on intra-cellular processing of the endogenously expressed protein [31, 32] . This perhaps explains why only a minority of the known EBNA1 CD4 epitopes are displayed on the LCL surface in amounts that are detectable by epitope-specific T cell clones, and those that are presented arise through intra-cellular processing pathways such as macroautophagy [32, 33] .
Figure 2 summarises a kinetic view of events characterising primary infection, from the time IM symptoms develop. Note that very little is known about the prior incubation period, although some evidence suggests that high virus load in the blood and the accompanying lymphocytosis only appear shortly before symptoms [1]. Interestingly, while latent virus load in the blood is rapidly brought under control during the disease course , high levels of asymptomatic virus shedding can be found in throat washings for several weeks or months [30, 34] . This suggests either that shedding is occurring from an immunologically protected site in the oropharynx or that the particular controls governing shedding are slow to develop and access that site.
EBV infection in primary immunodeficiencies affecting cellular immunity
While classical IM patients offer one important window into the biology of EBV infection, patients with primary immunodeficiencies affecting the NK and/or T cell systems offer another. The best known examples, the X-linked lymphoproliferative syndrome (XLP) and its relative XIAP, have recently been joined by several other primary immunodeficiencies predisposing to EBV-associated disease [reviewed [35] ]. These are of considerable interest but require cautious interpretation because patient numbers are small and, even where the genetic basis of the deficiency is known, its effects are rarely specific to just one arm of the cellular immune system.
There are currently three genetically-defined conditions with either a selective or preferential loss of NK cell function relative to that of T cells [reviewed [36] ]. All three are associated with increased susceptibility to various pathogens, including herpesviruses such as herpes simplex (HSV1) and varicella (VZV); however EBV is also implicated on occasions. The most NKspecific deficiency involves patients with a homozygous mis-sense mutation in CD16, the NK cell activating receptor for antibody-dependent cell cytotoxicity (ADCC Surviving patients in both studies had EBV-specific CD8 + memory T cell populations that were of normal size but markedly skewed towards an IFN-producing (effector-memory) phenotype, possibly reflecting on-going antigen challenge in vivo. One interesting possibility is that these patients are particularly susceptible to EBV because virus-transformation strongly upregulates the CD27 ligand, CD70, on the B cell surface [61] , and optimal recognition by EBV-specific CD8+ T cells may require the CD27-CD70 interaction as a co-stimulus.
A final example involves inactivating mutation of the X-linked gene encoding the magnesium transporter, MAGT1 [62] . Affected males have normal NK and i-NKT cell numbers but low CD4 + T cell counts, especially in the naive compartment, and a TCR signalling defect [63] .
Though susceptible to other infections, all 7 reported patients came to attention through persistent IM-like symptoms and high EBV loads, progressing in 4 cases to EBV-positive Blymphoproliferative disease or frank lymphoma. These patients had normal numbers of EBVspecific CD8 + memory T cells and NK cells; however, after in vitro expansion, both these effectors showed poor recognition of relevant target cell lines. Mg ++ -supplementation of the medium corrected the functional deficit by restoring expression of NKG2D both on the NK cells, where it serves as an activating receptor, and on the EBV-specific CD8 + T cells, where interactions with NKG2D ligands on the LCL surface optimised specific recognition. Remarkably, treating the MAGT1-deficient patients with Mg ++ supplements led to falling EBV loads in the blood, demonstrating the biological relevance of NK and/or T cell responses in setting the viral set-point in vivo [64] .
The special case of XLP and its relative XIAP
The most extreme example of genetic susceptibility to EBV involves young boys in whom primary infection leads to X-linked lymphoproliferative disease (XLP), a highly exaggerated form of IM, with high viral loads in infected B cells accompanied by massive CD8 + T cell and NK cell responses [65] . The resultant cytokine storm triggers haemophagocytic lymphohistiocytosis (HLH), leading in most cases to fatal bone marrow failure. Other boys with the same trait present with hypogamma-globulinaemia or B cell lymphoma, conditions that are not linked to (and may precede) EBV infection [66] [67] [68] . The XLP gene SH2D1A encodes a small adapter protein, SAP, that is expressed in T, NK and i-NKT cells and is involved in the signalling of cell-cell interactions mediated by members of the SLAM family of surface receptors [69] Interestingly, XLP patients have normal numbers of NK and T cells but lack i-NKT cells, fuelling speculation that i-NKT cells may play a role in controlling EBV. However, as discussed further below, SAP-negative T and NK cells also have specific functional defects that likely contribute to the disease.
Subsequently, a second X-linked condition with similarities to XLP was discovered and mapped to the nearby BIRC4 gene [70] . Its product, the X-linked inhibitor of apoptosis (XIAP) protein, is ubiquitously expressed and has both an anti-apoptotic function and multiple signalling pathway connections. Affected boys typically present with HLH symptoms that are often, but not always, linked to primary EBV infection; they may also present with hypogamma-globulinaemia but, in contrast to XLP, never with lymphoma. Just how close the relationship is between the two conditions remains a subject of debate [71, 72] . XIAP patients often have low numbers of i-NKT cells but normal NK and T cell numbers; however their T cells show an increased sensitivity to apoptotic stimuli ex vivo [70, 73] . How this immune phenotype relates to the XIAP disease phenotype is still poorly understood.
By contrast, work on SAP has illuminated many aspects of XLP pathogenesis. SAP binds to the cytoplasmic tails of SLAM family proteins expressed by NK, T and i-NKT cells and mediates signal transmission following the interaction of these proteins with their partners on other cell types. Interactions with B cells appear particularly dependent on two SLAM family members; one of these, NTBA, forms homotypic interactions with NTBA on the B cell surface whereas the other, CD244, binds to a B cell-specific protein, CD48, whose expression is dramatically upregulated by EBV infection (see Figure 3) . SAP deficiency is therefore especially damaging both to physiologic T cell-B cell communication, hence predisposing to hypogamma-globlinaemia [69] , and to the control of a B-lymphotropic virus: thus NK cells cannot kill HLA class 1-negative B cell targets [74] and EBV-specific CD8 + T cells, though they are induced in XLP patients, cannot recognise EBV-infected B cell targets [75] . The same deficient target recognition also protects XLP T cells from restimulation-induced cell death, the homeostatic control that normally regulates effector cell numbers [76] , hence explaining the extreme expansions and associated symptomatology one sees in the fatal IM-like disease.
The importance of SAP for CD8 + T cell control of EBV is most clearly shown by XLP-carrier mothers, in whom random X-chromosome inactivation produces both SAP-positive and SAPnegative populations in the T cell repertoire. EBV-specific CD8 + T cells in these carriers were exclusively SAP positive, while CD8 + T cells against other viruses were found in both populations [77] . Furthermore, careful re-analysis of XLP patients themselves has detected cases where small numbers of CD8 + T cells have regained SAP function by somatic reversion of the SH2D1A gene mutation. Such SAP-positive cells were only detectable in XLP patients who had survived EBV infection and indeed those cells appeared to be enriched for EBV-reactivities, suggesting that long-term virus carriage had driven the expansion of these rare revertants to detectable levels [78] .
Despite the presence of small reverted populations in most EBV-positive XLP patients studied to date, all such patients also have SAP-negative CD8 + T cell memory to EBV. Hence they have clearly mounted CD8 + T cell responses to primary EBV infection even though the SAP-negative effectors thus produced recognise EBV-infected B cells very poorly if at all [75, 77] . The implications for the priming of these responses are illustrated in Figure 3 . In XLP patients the initial priming and early expansion of the CD8 response might be driven less by direct CD8 + T/B cell contact, that is by the pathway envisioned for responses in immunocompetent individuals, and more by the cross-presenting DC pathway. As a result, the usual hierarchy of CD8 immunodominance among lytic cycle proteins (immediate early>early>late, reflecting antigen display on lytically-infected B cells) should be overturned. In particular, late structural proteins of the virus, released in abundance from lytically-infected cells and available to cross-presenting DCs, should compete more effectively for immunodominance. Antigen choice would therefore become much broader, indeed closer to that shown by the conventionally cross-primed CD4 response. Screening the hierarchy of EBV antigen specificities within the SAP-negative CD8 + T cell pool of XLP patients will allow this prediction to be tested.
Lessons from animal models
Lessons learned from EBV infections in the natural host can take us so far. However many outstanding issues, the very early events following infection of the naïve host, the establishment of latency in memory B cells, the relative contributions of innate and adaptive responses to immune surveillance, can only be resolved with the help of animal models. The restriction of gamma1-herpesvirus infections to primate hosts is a major challenge in that regard, but two models show particular promise.
Old World primates carry gamma1-herpesviruses that are genetically very close to EBV, persist in the B cell system and elicit both CD4 + and CD8 + antigen-specific T cell memory [79, 80] .
Furthermore the establishment of a specific pathogen-free colony of rhesus macaques has allowed such animals to be orally infected with their natural EBV-like agent, rhesus lymphocryptovirus (rhLCV) [81] . As recently reviewed [82] , now that the rhLCV genome can be manipulated genetically as a Bacterial Artificial Chromosome, the system has the ability to identify what role individual virus genes play in the acute and persistent phase of infection. Indeed, a serendipitous deletion in the gene encoding rh-BARF1, a secreted lytic cycle protein that blocks colony stimulating factor (CSF1) signalling, has already produced interesting results. Rh-BARF1 evasion of the host's innate CSF1 response increases virus replication in the oropharynx, and this leads on to higher loads in latent virus in the life-long B cell reservoir [83] .
A second complementary approach uses immunodeficient BALB/c Rag 2 -/-c -/-or NOD-scid c -/-mice reconstituted with the main human haemopoietic cell lineages from inocula of CD34 + human stem cells from cord blood or foetal liver [reviewed [84] ]. Initial studies showed that EBV infection of such animals by intraperitoneal injection induced virus-specific CD8 + T cell responses and that T cell depletion predisposes to virus-driven B-lymphoproliferative disease [85] [86] [87] . Interestingly, although the virus had to be delivered directly into the B cell system of these animals (by-passing the stage of virus replication in the oropharyynx), there was a detectable CD8 + T cell responses to lytic cycle epitopes, confirming that incoming virus can replicate in B cells of the naïve host. Analysing human T cell responses to any virus in such animals is complicated by the need to supply a human HLA-expressing thymic epithelium for selection of the T cell repertoire, either via HLA transgenesis or using a human thymic tissuecontaining organoid [86, 88, 89] . However, animals with successful reconstitution of the dendritic and NK cell compartments [90] [91] [92] allow one to study the very early immune response to virus infection, before T cells come into play. Very recent work in such animals has thrown important light on the early events of EBV infection [93] , detecting marked expansion of NK cells with an early-differentiation CD94 + NKG2A + KIR -phenotype. Note that this phenotype is either identical to or the next differentiation step after [94] the tonsillar NK cell compartment that showed superior inhibition of EBV driven B cell transformation in vitro [10, 11] . Antibody-mediated depletion of these cells, but not of more differentiated NK cells, led to increased EBV genome load in blood and spleen (with especially high DNA-aemia in plasma) and increased expression of lytic EBV antigens in infected organs. This effect of NK cell depletion on viral load was only observed using wild-type virus, not with a replication-deficient EBV mutant, thereby clearly implicating a role for NK cells in controlling early virus replication. Furthermore NK cell depletion and the consequent increase in virus load led to a greatly expanded CD8 + T cell response, associated with elevated cytokine levels and lymphadenopathy; again the effect was only observed with replication-competent wild-type virus. These findings provide the first experimental evidence, albeit in an animal model, that NK cells and T cells play important complementary roles in combating primary EBV infection. As illustrated in Figure 4 , they suggest that NK cells, particularly the early-differentiated subset that predominates in early childhood, act initially to limit lytic EBV replication and thereby avoid the massive expansion of virus-specific CD8 + T cells that culminates in IM-like immunopathology.
Conclusions and future challenges
EBV is a very significant human pathogen yet, in most individuals, is carried as a completely asymptomatic infection contained by host immune controls. Given the global impact of EBVassociated malignant and non-malignant conditions, understanding the full spectrum of those immune controls and how their disturbance can lead to disease is a hugely important goal. Here we have described three current lines of enquiry that will remain important in pursuing that goal: (i) prospective studies on IM and, where possible, on the exaggerated form of this disease seen in XLP patients, (ii) monitoring EBV infections in the ever-increasing range of genetically-defined primary immune deficiency states, and (iii) experimental EBV infections in the rhesus macaque and humanised mouse models. With these studies as a basis, there are many further questions to address. How might EBV infection, particularly a history of IM, predispose both to an autoimmune disease, multiple sclerosis [95] and to Hodgkin Lymphoma [96] ? Might an inflammatory environment, particularly that induced by a high EBV load in IM, allow rogue T cell priming, leading in one case to cross-reactive auto-immune recognition of neuronal cells and in the other to wrongly polarized T cells that nurture rather than deter lymphoma growth? At the same time, the immune response can be used for good rather than ill; adoptive T cell therapy has shown how a restoration of virus-specific T cells can successfully treat EBV-driven Blymphoproliferative disease [56; Bollard et al, 2012], so how best to exploit these same cellular responses to target other EBV-positive malignancies [97] ? Arguably most important of all, how best to design a prophylactic vaccine that, even if it cannot prevent primary infection, may limit virus load and protect against EBV-associated disease [98] ? As we approach the 50 th anniversary of the discovery of EBV [99] , the virus' challenge to the immunologist remains as potent as ever. [A] In the immunocompetent host: Two features of EBV-induced CD4 + T cell responses, the broad spectrum of antigens targeted (including many late lytic cycle proteins) and the delayed primary response to EBNA1 (a poorly-released antigen), both suggest a dominant role for antigen release and cross-presentation as the main driver of these responses; it seems likely that dendritic cells play a key role in such cross-presentation, although EBV-infected B cells can also acquire viral antigens released from infected neighbours and cross-present to CD4 + T cells.
Conversely two features of the EBV-induced CD8 + T cell response, the marked focus on epitopes from immediate early and some early proteins of the lytic cycle (reflecting epitope display on naturally-infected cells) and the rapid primary response to EBNA1 (a poorly-released antigen), both suggest that the CD8 response is predominantly driven by direct contact with infected B cells.
[B] In XLP patients : In the absence of SAP, T cell/B cell recognition is impaired. This should not affect the antigenic profile of CD4 + T cell responses since the main cell-cell interaction driving these responses, CD4 + T cells and cross-presenting dendritic cells, should be intact.
However, CD8 + T cell responses may now also become dependent upon the cross-presenting pathway; as a result, the antigen profile of the CD8 response is predicted to be broader and no longer reflect the hierarchy of epitope display on naturally infected B cells. Note that the failure of T cell/B cell recognition in XLP also impairs receipt of the TCR-restimulation signals that normally regulate CD8 + T cell expansions, thereby promoting hyper-expansion of the response and its attendant immune pathology. 
